New drug cocktail aims to stop transplant complication
NCT ID NCT02891603
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 33 times
Summary
This study tested a new approach to prevent graft-versus-host disease (GVHD), a serious complication that can occur after a stem cell transplant. Researchers combined the drug pacritinib with two standard immune-suppressing medicines (sirolimus and tacrolimus) in 40 adults receiving a transplant from a matched donor. The goal was to see if this triple therapy could safely lower the risk of acute GVHD.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAFT VS HOST DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States
Conditions
Explore the condition pages connected to this study.